Metraipolis › archive › dc_c2ca5e5f353f

Prevalence and predictive testing preferences for breast cancer treatment side effects — Europe PMC PMID:41261260

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41261260
DOI
10.1007/s00520-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-08T10:15:08.603Z
SHA-256 of the archived text
462dc6b3e6925e8c544d75d5c178787b55507ddfb05006b4e7829e52be397808
Stable URL of this page
https://metraipolis.com/documento/dc_c2ca5e5f353f

How to cite

Prevalence and predictive testing preferences for breast cancer treatment side effects — Europe PMC PMID:41261260 — Europe PMC (en), https://europepmc.org/article/MED/41261260 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c2ca5e5f353f (Metraipolis archive dc_c2ca5e5f353f, sha256 462dc6b3e6925e8c544d75d5c178787b55507ddfb05006b4e7829e52be397808)
BibTeX
@misc{dcc2ca5e5f353f,
  title = {Prevalence and predictive testing preferences for breast cancer treatment side effects — Europe PMC PMID:41261260},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41261260},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c2ca5e5f353f; sha256 462dc6b3e6925e8c544d75d5c178787b55507ddfb05006b4e7829e52be397808},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41261260. Agents can read the archived copy with the MCP tool read_document.